Literature DB >> 12438295

Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT).

Kristin E Ellison1, Gail E Hafley, Kathleen Hickey, Joyce Kellen, James Coromilas, Kenneth M Stein, Kerry L Lee, Alfred E Buxton.   

Abstract

BACKGROUND: Beta-blockers are known to reduce total mortality and sudden death in survivors of recent myocardial infarction. The effects of these agents in patients at high risk for sudden death with remote infarction are not clear. METHODS AND
RESULTS: We analyzed the effect of beta-blockers on outcomes in 2096 patients with coronary artery disease, ejection fraction < or =40%, and spontaneous nonsustained ventricular tachycardia enrolled in the Multicenter UnSustained Tachycardia Trial (MUSTT). Forty-five percent of 702 patients with inducible sustained ventricular tachyarrhythmia and 35% of 1394 patients without inducible tachycardia were discharged from hospital receiving beta-blockers. Patients treated with beta-blockers were younger and had higher ejection fractions, higher rates of recent angina, and more recent infarction. beta-Blockers were associated with decreased total mortality for the entire study population (5-year mortality 50% with beta-blockers versus 66% without beta-blockers; adjusted P=0.0001). The mortality benefit associated with beta-blockers was present in patients with and without inducible tachycardia, except those treated with implantable defibrillators. There was no significant effect of beta-blocker therapy on the rate of arrhythmic death or cardiac arrest (adjusted P=0.2344).
CONCLUSIONS: beta-Blocking agents have beneficial effects on survival of patients having characteristics of those enrolled in the MUSTT trial. These effects do not appear to be due to a specific antiarrhythmic effect of beta-blockers. The beneficial effects of beta-blockers were demonstrable in all patients except those treated with implantable defibrillators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438295     DOI: 10.1161/01.cir.0000038499.22687.39

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

1.  Increased long-term mortality in women with high left ventricular ejection fraction: data from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) long-term registry.

Authors:  Catherine Gebhard; Monika Maredziak; Michael Messerli; Ronny R Buechel; Fay Lin; Heidi Gransar; Stephan Achenbach; Mouaz H Al-Mallah; Daniele Andreini; Jeroen J Bax; Daniel S Berman; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Kavitha Chinnaiyan; Benjamin J W Chow; Ricardo C Cury; Augustin DeLago; Gudrun Feuchtner; Martin Hadamitzky; Joerg Hausleiter; Yong-Jin Kim; Jonathon Leipsic; Erica Maffei; Hugo Marques; Pedro de Araújo Gonçalves; Gianluca Pontone; Gilbert L Raff; Ronen Rubinshtein; Leslee J Shaw; Todd C Villines; Yao Lu; Erica C Jones; Jessica M Peña; James K Min; Philipp A Kaufmann
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-04-01       Impact factor: 6.875

Review 2.  Optimising the use of beta-adrenoceptor antagonists in coronary artery disease.

Authors:  Kristin E Ellison; Gaurang Gandhi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Minimally invasive transtracheal cardiac plexus block for sympathetic neuromodulation.

Authors:  Fabrizio R Assis; Diana H Yu; Xun Zhou; Sunjeet Sidhu; Anisha Bapna; Zoar J Engelman; Satish Misra; David R Okada; Jonathan Chrispin; Ronald Berger; Kaushik Mandal; Hans Lee; Harikrishna Tandri
Journal:  Heart Rhythm       Date:  2018-07-31       Impact factor: 6.343

Review 4.  The Real Role of β-Blockers in Daily Cardiovascular Therapy.

Authors:  Csaba András Dézsi; Veronika Szentes
Journal:  Am J Cardiovasc Drugs       Date:  2017-10       Impact factor: 3.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.